Information Provided By: 
Fly News Breaks for July 28, 2015
TEVA
Jul 28, 2015 | 08:03 EDT
Citi analyst Liav Abraham raised his price target for Teva (TEVA) to $86 saying the stock remains a preferred name following the acquisition of Allergan's (AGN) generics business. Greater earnings and cash flow visibility should enable investors to look past Copaxone towards the longer term growth drivers of the company, Abraham writes in a research note. He keeps a Buy rating on Teva.
News For TEVA From the Last 2 Days
